Dr. Connelly has 20 years of experience in academia and industry, including more than 12 years in pharmaceutical and in vitro diagnostic research and development. She has a PhD in Pathology and Immunology from Stony Brook University School of Medicine and an MBA in Pharmaceutical Management from LeBow College of Business, Drexel University. She is a Fellow of the American Heart Association and has published >97 publications and patents in her areas of expertise. Previous to accepting a position at LipoScience, Dr. Connelly worked at Janssen R&D working on therapeutics for atherosclerosis, diabetes and obesity. Dr. Connelly has spent the last 3 years applying her scientific expertise and leadership experience toward the development and clinical validation of new nuclear magnetic resonance (NMR)-based biomarkers for various disease indications including cardiovascular disease, inflammation and metabolic disorders such as metabolic syndrome, diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and liver fibrosis.